Researchers Examine Suicide Rate Changes Due to COVID-19

Article

Suicide rates in 2020 have increased most in individuals younger than 30 years old.

Haruka Sakamoto, MD, MPH

Haruka Sakamoto, MD, MPH

There is undoubtedly psychiatric issues associated with the coronavirus disease 2019 (COVID-19), with many researchers concerned over a potential jump in suicide rates.

Previous research has indicated the suicide rate has not increased in high-income countries due to the pandemic, but a recent analysis in Japan shows excess suicide deaths in women, but not men between July-September 2020.

A team, led by Haruka Sakamoto, MD, MPH, Department of Health Policy and Management, Keio University, assessed whether suicide rates in Japan increased between April and November 2020 compared to the suicide rates in 2019.

How They Analyzed The Data

In the cross-sectional study, the investigators used national data collected by the Ministry of Health, Labor, and Welfare between 2016-2020 on the monthly number of individuals who died of suicide in Japan between January-November of 2016-2020.

The investigators sought main outcomes of monthly suicide rates, calculated as the number of individuals who died of suicide dived by the total population. They used a difference-in-difference regression model to estimate the change in monthly suicide rates during the study period in 2020 compared to the same time period in 2016-2019.

Overall, there were 90,048 individuals who died of suicide between 2016-2020 included in the analysis, 68.1% were males.

Month-by-Month Differences

In the difference-in-difference analysis of the just the males in the study, the researchers found no increase in suicide rates in 2020 compared to 2016-2019 between April and September. However, they did find an increase strictly in October (difference-in-difference, 0.40; 95% CI, 0.14-0.67; suicide deaths per 100,000 population) and November (difference-in-difference, 0.34; 95% CI, 0.07-0.60 suicide deaths per 100,000 population).

For women, the suicide rates in 2020 increased in July (difference-in-difference, 0.24; 95% CI, 0.09-0.38 suicide deaths per 100,000 population), August (difference-in-difference, 0.30; 95% CI, 0.16-0.45 suicide deaths per 100,000 population), September (difference-in-difference, 0.29; 95% CI, 0.15-0.44 suicide deaths per 100,000 population), October (difference-in-difference, 0.62; 95% CI, 0.48-0.77 suicide deaths per 100,000 population), and November (difference-in-difference, 0.29; 95% CI, 0.15-0.44 suicide deaths per 100,000 population).

After the researchers conducted a secondary analysis comparing 2020 suicide rates with the expected rates based on trends between 2011-2019, the team found the increases in suicide rates were most pronounced among males younger than 30 (November: observed vs expected RR, 1.48; 95% CI, 1.26-1.71) and women aged younger than 30 years (October: observed vs expected RR, 2.14; 95% CI, 1.76-2.52) and 30-49 years (October: observed vs expected RR, 2.30; 95% CI, 2.01-2.58).

“These findings suggest that compared with previous years, suicide rates in Japan in 2020 increased in October and November for men and in July through November for women,” the authors wrote.

Since the beginning of the pandemic there has been concerns over the impact of mitigation measures like social distancing and shelter-in-place restrictions could have on the collective mental health of the population.

The study, “Assessment of Suicide in Japan During the COVID-19 Pandemic vs Previous Years,” was published online in JAMA Network Open.

Related Videos
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Andrew Miller, PhD: Inventor of KarXT Discusses Pivotal EMERGENT-2 Data
New Drug Application for MDMA-Assisted Therapy for PTSD Awaits FDA Approval
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Rishi Kakar, MD: EMERGENT trials, FDA Accepts Xanomeline-Trospium Application
© 2024 MJH Life Sciences

All rights reserved.